When does vismodegib’s patent expire?
I don’t have enough information in the provided materials to state the exact vismodegib patent expiry date (or which specific patent(s) drive exclusivity). Patent expiry depends on the filing and priority dates in each jurisdiction and which patents are still in force.
Which country’s expiry date matters?
Patent status is country-specific. A vismodegib patent expiry date in the United States can differ from Europe, the UK, or other markets because of different filing dates, patent term calculations, and any extensions or adjustments tied to regulatory review.
Does vismodegib have exclusivity beyond patents?
Even after a patent’s scheduled expiry, additional layers can delay generic or biosimilar competition depending on the jurisdiction. These can include supplementary protection mechanisms (for example, in some European systems) and other regulatory exclusivity rules. The exact impact for vismodegib depends on the applicable country and the specific regulatory history.
How can you check the real “expiry” that affects generics?
To find the practical date when lower-cost competition can start, you typically need:
- The jurisdiction (US vs. EU vs. UK vs. others).
- The specific patent numbers listed for the drug in that jurisdiction.
- Whether any term adjustments/extensions apply and whether those patents are still active.
- Any regulatory exclusivity protections that are separate from patents.
What to provide so I can give the exact date
Share the jurisdiction (for example, “US” or “EU”) and, if you have it, the patent number(s) or a link to the patent register page you’re using. With that, I can translate the referenced filings into the expected expiry timeline and explain which protections likely control generics entry.
Sources
None provided.